Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 212

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 212
---
100%
  
    Deemed dividend related to Series C Common Warrants 
     (84,083) 
     -  
     (84,083) 
     100%
  
    Net loss attributable to common stockholders 
    $(35,571,847) 
    $(4,748,348) 
    $(30,823,499) 
     649.1%

Research
and Development Expenses

Research and
development expenses were $5,662,000 for the six months ended June 30, 2025 as compared to $4,383,000 for the six months ended June
30, 2024, reflecting an increase of $1,279,000. The increase was primarily attributable to an increase in clinical expenses of
$2,362,000, and an increase in scientific consulting fees of $496,000. In the first quarter of 2025, we began clinical trials
related to the IND for CER-1236. This increase was primarily offset by a decrease in lab expenses of $461,000 primarily attributable
to a decrease in toxicology studies performed in the 2025 period as compared to the 2024 period, a decrease in research and development salaries and benefits of
approximately $989,000 which included a decrease in stock-based compensation expense of $723,000 primarily attributable to a
decrease in accretion in stock-based option expense and a decrease in bonuses paid of $132,000, and a decrease in other research and
development costs of $129,000.

The
Company anticipates that its R&D expenses will significantly increase in the future as the Company increases headcount, compensation
expense, and contracted services for preclinical and clinical development of its product candidates, as well as for manufacturing of
clinical product to be used in clinical development.

36

General
and Administrative Expenses

General
and administrative expenses were $4,013,000 for the six months ended June 30, 2025 as compared to $5,318,000 for the six months ended
June 30, 2024, reflecting a decrease of $1,305,000. The decrease during the six months ended June 30, 2025 as compared to the six months
ended June 30, 2024, was primarily due to a decrease of $1,750,000 in underwriting fees from the PBAX initial public offering, which
were incurred upon the consummation of the business combination in